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Abstract
This paper summarises tuberculosis (TB) research over almost 30 years in Karonga District,
northern Malawi, an area typical of much of rural Africa. The dominant factor has been HIV,
which arrived in the district about 1980, leading to an increase in TB incidence to a peak of
approximately 65 smear-positive pulmonary cases/100,000 in 2000. Tuberculin surveys indicate
annual risks of M. tuberculosis infection of approximately 1%, thus most of the population is
uninfected and at risk of primary infection and disease. Molecular epidemiological studies
demonstrate that about two thirds of TB arises from recent infection, but recognisable recent
contact is responsible for only about 10 % of disease. By 2001, 57% of TB was directly
attributable to HIV, implying that it would have declined were it not for HIV. HIV infection
increases the risk of TB most among young adults, and greatly increases the risk of recurrence
from new infection after treatment. Mortality rates in the HIV-infected are high, but there is no
association of HIV with drug resistance. Other risk factors with relatively smaller effects include
age and sex, contact, several genetic polymorphisms and area.
Neither one nor two doses of BCG provides protection against adult pulmonary tuberculosis,
despite protecting against leprosy. Skin test surveys, cohort studies and comparative
immunological studies with the UK suggest that exposure to environmental mycobacteria provides
some protection against TB and that BCG’s failure is attributable partly to this widespread
heterologous exposure masking effects of the vaccine.
Drug resistance has remained constant (<10%) over more than 20 years. Immunotherapy with
Mycobacterium vaccae provided no benefit, but treatment of HIV-positive patients with
cotrimoxazole reduced mortality. The Karonga programme illustrates the value of long-term
population-based studies to investigate the natural history of TB and to influence TB control
policy. Current studies focus on immunological markers of infection, disease and protection, and
on elucidating the impact of anti-retroviral therapy on TB incidence at population level.
Introduction
A large research project on the epidemiology of mycobacterial infection and disease was
initiated in Karonga, a district in northern Malawi, in 1979. The programme’s focus evolved
over subsequent years, tracing a decline in leprosy, the emergence of HIV, and a great
increase in tuberculosis. The work has included classical and molecular epidemiology,
vaccine and treatment trials, as well as demography, immunology, and genetics. This paper
describes the contribution of these studies to our understanding of tuberculosis, from natural
history to control, including interactions with HIV, and immunological interactions with
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other mycobacterial infections. It illustrates the value of long-term community-wide studies
for understanding a complex disease in a population context.
The overall programme, known as the Karonga Prevention Study (KPS) has also made
significant contributions in other areas, particularly in leprosy and HIV/AIDS. A full
publication list is available on www.lshtm.ac.uk/ideu/kps
Setting and methods
Karonga District is bordered to the east by Lake Malawi and to the west by the Central
African (Nyika) Plateau (Figure 1). The population consists primarily of subsistence
farmers, fishermen and small traders, and has grown from approximately 112,000 to over
250,000 over the past 30 years. The area was selected for its high prevalence of leprosy and
its isolated situation, a factor associated with relatively little population movement. Two
total population surveys were carried out in 1979–1984 and 1986–1989. 1,2 These surveys
developed methods for precise grid mapping (later translated to GIS coordinates) and for
accurate identification of individuals seen repeatedly, in different circumstances, over time.
These and other methods have been continued ever since, enabling linking of interview data,
clinical examinations and biological samples within and between studies. The linked
databases now contain data from 800,000 contacts with 300,000 individuals.
KPS staff are stationed at all the major health facilities, where they screen inpatients and
outpatients for symptoms of tuberculosis. Additionally, everyone participating in
community-based studies is asked about chronic cough. Surveys have confirmed that the
district-wide tuberculosis case detection rate is high. The KPS laboratory has processed all
biological samples from district tuberculosis suspects since late 1985, undertaking both
sputum smear microscopy and culture. Isolates have been sent to the UK for species
confirmation, drug sensitivities and molecular typing. The KPS works closely with the
Malawi National TB Programme and acts on its behalf in Karonga District in co-operation
with the District Tuberculosis Officer, enhancing the care for tuberculosis patients in the
district. The numbers of diagnosed tuberculosis cases increased greatly over the history of
the KPS. The incidence of confirmed smear-positive pulmonary disease peaked in the mid-
late 1990’s at around 130/100,000 adults per annum (this represents approximately
65/100,000 total population), and then declined to its current level of below 80/100,000
adults3.
HIV data are available on the Karonga population in various contexts: clinical settings;
large, ongoing case-control studies; antenatal clinic surveillance and house-to-house
surveys. The earliest infections were identified from archived specimens collected in 19824,
and by 1988 HIV testing procedures had been established at the site. HIV prevalence was
3.9% of the 15-49 year-old population by 1988-1990, increased to 11% in 1991-1993 and
reached a plateau of around 13% in 1998-20015,6.
BCG vaccination was introduced in Karonga district in mass school campaigns in the mid
1970s. Since 1990 it has been given at first health system contact, as part of the Expanded
Programme on Immunization.
Epidemiology of M. tuberculosis infection
The patterns of incidence and prevalence of M.tuberculosis infection in the Karonga
population, have been described in detail, through analysis of population-based tuberculin
survey data conducted with consistent and rigorous protocols7 (using RT23 tuberculin (2IU)
throughout). More than 63,000 individuals were tested in the first total population survey
(1979–1884) and more than 45,000 in the second (1986–1989), making this the largest and
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most detailed dataset on tuberculin skin tests collected in Africa7,8. Seven thousand
individuals were tested in both of the surveys and in addition approximately 9,000
tuberculin tests have been carried out from 1996-2008 in the context of studies of the
household transmission of M.tuberculosis and of the immunogenicity of BCG and other
vaccines3,9.
Figure 2 shows the pattern of delayed-type hypersensitivity (DTH) to tuberculin among
females without a BCG scar, by age, in the early 1980s and Figure 3 shows the proportion
with indurations above 10 mm, by age, sex and BCG scar status7. These patterns are typical
of many populations10,11, the increase by age reflecting cumulative lifetime exposure and
the plateau and decline after age 50 reflecting ageing of the immune system. Trends are
similar between males and females until approximately 15 years of age; males show
consistently higher prevalence above this age. This too is typical of many populations10,11,
though less understood: it may reflect in part a greater likelihood of exposure among adult
males compared to females, but may also reflect a sex-difference in immune response to
infection – males generating a stronger and/or more durable DTH response to
M.tuberculosis, compared to females.
Such data are often used to derive annual risks of M.tuberculosis infection, though such
inferences are more complex than widely appreciated7,12. Analyses of the KPS age-specific
prevalence data by conventional methods provided estimates of annual rates of infection
ranging from approximately 0.5 to 1.1 percent per annum, depending upon the criterion used
for tuberculin “positivity” (for example a simple 10 mm criterion, or assuming a symmetric
distribution of true positive responses around 17 mm, ie the “mirror method”)7,13 Mixture
analysis methods which attempt to distinguish sensitivity attributable to M.tuberculosis from
that attributable to exposure to other mycobacteria14, suggest prevalence (thus incidence)
estimates intermediate between the other methods.
The 7,000 individuals tested in both KPS surveys allowed longitudinal estimation of
tuberculin conversion and reversion rates in individuals7. A change from below to above 10
mm with an absolute increase of at least 6 mm was defined as conversion15. Reversion was
defined in equivalent but opposite terms. Amongst individuals without a BCG scar,
conversion rates increased and reversion rates decreased with age, as observed
elsewhere16-19 . Analysis of Karonga data indicates that such apparent trends may be
artefacts due to instability of the tuberculin test, being what would be expected if infection
risks were actually constant by age. The proportion of test negatives which are false (due to
problems with the test) will rise with age, as the true prevalence of positivity increases with
age. As positive individuals who were falsely negative on an initial test will appear to have
converted if their second test is (correctly) positive, this will produce an apparent increase in
conversion risk with age. The reverse logic applies to reversion rates - in young infants a
high proportion of initial “positive” tests will be false and with a subsequent negative test,
will be interpreted as reversion. Many authors have commented on the instability of
tuberculin testing (eg it is well known that exposure to environmental mycobacteria induces
tuberculin DTH, that induced DTH to BCG rises and then falls after exposure20; and that
some virus infections induce temporary suppression of DTH) but these KPS analyses
provide an unusually detailed insight into this instability and have important implications for
estimates of infection risks.
Analysis of tuberculin tests carried out on 2,400 individuals in the months after BCG
vaccination further our understanding of DTH responses, showing that it rises to a peak 1 to
3 months after BCG exposure, with almost all individuals making a response at this time,
and then declines20 (Figure 4). Whether an equivalent trend occurs after M tuberculosis
infection is unclear, as the decline may reflect the disappearance of BCG bacilli.
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Comparisons of tuberculin reactivity with whole blood in vitro assays of interferon gamma
release after exposure to M.tuberculosis RT48 antigen reveal moderately strong positive
correlations9, but with notable exceptions: a small proportion of individuals with strong
DTH show no IFNg release, and a small proportion with no measurable DTH release large
quantities of IFNg on exposure to similar M.tuberculosis antigens. Other researchers have
found analogous inconsistencies between skin test and in vitro responses to mycobacterial
antigens21,22, but the implications for inferring infection and protective immunity are
unclear.
The estimate of around 1% infection risk in Karonga is similar to that for many high burden
countries today, and to Europe in the mid 20th century (after declining from much higher
levels). The highest infection risks today appear to be 3 %- 4% in the Western Cape of
South Africa.
Importantly, this estimate means that, even were infection life-long, the large majority of the
population of Karonga (median age approximately 15) at any given time are not infected
with M.tuberculosis. Most individuals in such a population are thus at risk of primary
infection and primary tuberculosis disease.
Recent versus latent infection in disease
There has been a long-standing debate over the relative importance of reactivation of past
infection versus recent infection or reinfection as causes of tuberculosis disease in adults.
The development of IS6110 based molecular fingerprinting23 has provided a tool for
investigating this issue, by distinguishing “strains” of M tuberculosis. The sharing of
identical strains by cases suggests recent transmission rather than reactivation of old
infection, and so the extent of “clustering” (ie the proportion of cases who have a strain
common with at least one other case) in a population can be used to infer the extent of recent
transmission24. These studies are most informative when, as in Karonga, they are conducted
in whole populations over several years25.
Molecular fingerprinting data are available at KPS from 1996. The proportion of cases who
had a strain common to another case within the study period (ie were “clustered”) was 72%,
among the highest recorded in any setting26. Using our longitudinal data, we calculated the
proportion of cases clustering with cases diagnosed one to eight years previously. The
maximum proportion clustered was reached within a 4-year time window, indicating that
approximately two thirds of cases were due to recent transmission. This appeared to be
stable over recent years.26 Analysis of clustering by time windows avoids underestimation
due to incomplete inclusion of clusters in studies with shorter time frames. Having a strain
in common with other cases became less likely with increasing age of HIV-negative patients
as expected, since the proportion of reactivation disease will increase with age26.
Role of recent known contact with smear positive cases
One corollary of a high proportion of cases arising from recent infection is that contact
tracing might be useful in tuberculosis control, with an effect which is measurable in the
short-term. However, investigation of same-strain clusters in Karonga revealed only 11% of
clustered cases had an identifiable epidemiological link within their cluster27. We asked all
confirmed tuberculosis patients about known prior contacts with tuberculosis, and also
identified contacts from the project database27. Transmission from identified smear-positive
putative source contacts was only confirmed for 44% of family and household contacts, and
a lower percentage for other contacts. Some cases will have arisen from reactivation of
latent infection (non-clustered), but the implication is that even tuberculosis patients with
disease arising from recent infection who have recent smear-positive cases in their family or
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household, may well have acquired their infection elsewhere. Mixed strain infection could
account for some of the differences although even in a high incidence area, they are thought
to be unusual28.
Using the proportion of epidemiologically-linked cases for whom transmission was
confirmed and the prevalence of household or family contacts, we estimated that 9-13% of
all cases were due to recent transmission in the family or household27. Using an alternative,
case-control approach we confirmed that identifiable recent contact with known smear-
positive cases accounted for only 12.5% of the tuberculosis burden, nearly half of that (5%)
attributable to having nursed, or shared a bedroom with, a relative with smear-positive
pulmonary tuberculosis29. The low proportion of tuberculosis attributable to identifiable
links is consistent with findings from South Africa and India (using different methods)30-32.
Although the risk of infection in household contacts of smear-positive tuberculosis cases in
these and similar settings is greatly increased33 compared to those without such contacts, all
our findings are consistent with the large majority of M.tuberculosis transmission in this
setting arising from casual contact.
Role of different strains
Investigation of the clusters also identified particular strains and strain families, some of
which are common worldwide. In Karonga the Beijing genotype accounted for 4.3% of
strains. It appears to have increased over time, and was fully drug sensitive34.
Impact of HIV on rates of disease, recurrence and transmission
Over the history of the KPS, by far the strongest risk factor for tuberculosis in Malawi, as
elsewhere, has been HIV. Although the effect of HIV on risk of M.tuberculosis infection is
unknown, HIV infection increases the risk of disease following both latent and recent
infection, but not necessarily to the same extent, and HIV also affects the course of disease
and the infectiousness of cases. Although these patterns have been investigated in many
contexts35, the KPS incorporates the only long-term population-based molecular
epidemiological study of tuberculosis in an area with a high prevalence of HIV. It has
therefore been uniquely placed to assess the effect of HIV on different mechanisms of
disease.
A case-control study in Karonga in 1988-1989 found that the odds ratio for the association
of tuberculosis with HIV infection was 7.4 (95% ci 3.3-16.7%)36, at which time 28% of
confirmed tuberculosis patients were HIV-positive37. A cohort study gave similar results,
recording tuberculosis incidence up to 1996 in 11,000 individuals with known HIV status
seen in the 1986-89 survey, and finding a relative risk of 7.1 (95% ci 3.2-15.7)38 In a case
control study among tuberculosis cases diagnosed in 1996-2001 the odds ratio for the
association with HIV infection had increased to 12.0 (9.0-16.1). These results reflect the
increasing proportion of prevalent HIV-infected individuals with more advanced
immunosuppression as the HIV epidemic progresses. By this time 64% of confirmed
tuberculosis patients were HIV-positive39 and this proportion has remained constant.
Estimates of the proportion of smear-positive tuberculosis cases directly attributable to HIV
increased from 17% in 1988-1990 to 57% in 2000-2001. These estimates do not account for
increase due to onward transmission from HIV-positive cases. We estimated that over the
same period the rate of smear-positive tuberculosis in adults would have decreased from
0.78/1000 to 0.45/1000 in the absence of HIV, and by 2003-2005 to 0.35/100037 (Figure 5).
There is some evidence that HIV increases the risk of disease following recent infection
more than that due to reactivation. It would be expected that the relative risk for the
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association of HIV and TB would increase with age, reflecting increasing
immunosuppression in those infected longer with HIV. However in Karonga39 (Figure 6)
and elsewhere40 the relative risk of tuberculosis in those with HIV infection is higher in
younger adults than in older adults. Since younger adults are less likely than older adults to
have reactivation disease, this is consistent with HIV infection having a greater effect on
disease following recent infection.
An association of HIV with cases having strains in common (clustered) might suggest that
HIV has a greater influence on disease following recent infection than on disease following
past infection, although this is complicated by lower infectiousness of HIV-positive patients
and by the difficulty of establishing the sequence of transmission within a cluster. In fact,
HIV infection has been associated with clustering in some studies but not in others24,30,41.
Where HIV and tuberculosis are only present in subgroups of the population, an association
with clustering may represent increased opportunity for transmission (eg in nosocomial
settings) and thus not reflect any differences in mechanism of disease. Only a few, mostly
small, studies are in populations with generalised HIV epidemics and the results are
variable30,41-47. In Karonga, HIV infection is associated with clustering in adults aged 45
years or older but not in younger age groups (in which the proportion clustered was already
very high)26 with no association between HIV and cluster size48.
HIV-positive tuberculosis patients have high mortality rates. In our setting, for patients with
smear-positive pulmonary tuberculosis, HIV increased the mortality of smear-positive
pulmonary tuberculosis 6-fold during treatment, and 8-fold thereafter49, although it did not
influence the smear conversion rate. Mortality rates both during and after treatment depend
on the patient population. In a comparison of case fatality rates in Karonga and Lusaka
(Zambia) among HIV-positive tuberculosis patients using data from the M vaccae trial (see
below), higher rates found in Karonga could be almost entirely explained by patients being
older and with more advanced HIV disease50.
Using molecular fingerprinting, rates of recurrence due to relapse and reinfection were
calculated over eight years. Similar rates of relapse were found in HIV-negative and HIV-
positive patients, but disease due to reinfection was found to be rare in HIV-negative
patients (0.35 /100 person years)51, though as common as relapse in HIV-positive patients
(2.23/100py). This was the first population-based study to estimate rates of relapse and
reinfection by HIV status.
Several studies have investigated the relative infectivity of HIV-positive tuberculosis
patients by examining tuberculin skin test conversion in household contacts. In general these
have suggested lower transmission from HIV-positive than from HIV negative cases52-54,
which might reflect either different pathology or earlier treatment if HIV-infected patients
sicken and seek care more quickly. In the KPS, we examined HIV status of smear-positive
index cases and compared M.tuberculosis strains with cases who named the index case as a
putative source. We found that if the index case was HIV-positive they were only half as
likely as HIV-negative index cases to be confirmed as the source of infection by molecular
fingerprinting27. In addition, HIV-positive tuberculosis patients were less likely than HIV-
negative patients to be identified as prior contacts of subsequent tuberculosis cases even
when adjusted for smear-positivity and closeness of contact.29 Nevertheless, despite the
lower transmission, because approximately two thirds of smear-positive patients in the area
are HIV-positive, we estimate that nearly half of the transmission of M.tuberculosis in this
setting is from HIV-positive patients27.
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Effects of gender
In Karonga, as elsewhere there is a distinct difference in tuberculosis patterns by sex (Figure
7), with excesses in younger women and older men37,39. The excess in younger women is
largely attributable to the higher HIV prevalence in women in these age groups. Recent
close contact with tuberculosis patients may also explain some of this gender
distribution29,39, as young women in this community preferentially perform the nursing
roles within the family. Women were more likely than men to have strains in common with
other patients26. However among those with clustered strains, being part of a large cluster
was more frequent in men, in younger adults and in the urban area48. The sex pattern is
consistent with women being more likely to be infected within the home (therefore being
identified as clustered within the study population, but in small clusters) and men being
more likely to be infected outside their homes (therefore either in large clusters, or not
clustered if infected outside the study area)48.
Adult women are less likely than adult men to have a “positive” tuberculin skin test,
regardless of the criterion used (Figure 3) 7 This may reflect a different immune response to
earlier infection or a lack of exposure, due to social patterns changing after childhood. Lack
of prior infection may leave young adult women more susceptible than men to primary
infection and primary disease. Case-control studies in Karonga found no effect of cooking-
smoke exposure or pregnancy on the risk of tuberculosis in women39.
Diagnosis
KPS has followed standard diagnostic algorithms and procedures for identifying pulmonary
tuberculosis cases, using smear microscopy and culture of biological samples from
tuberculosis suspects in a well-functioning laboratory with rigorous quality control. In the
Karonga setting it was found that 97% of those who were smear-positive on three smears
could have been identified with only two smears, with similar sensitivity and specificity,
using culture as gold standard, and that this was not affected by the HIV status of the
tuberculosis patient55. This has contributed to recommendations that overstretched TB
control programmes with appropriate laboratory quality control may safely reduce the
numbers of sputum smears in screening56. In addition, a diagnostic clinical scoring system
(validated by fine needle aspirate or histology) was developed to distinguish tuberculous
lymphadenitis from lymphadenopathy of other causes (primarily HIV-associated) in a
setting where HIV had greatly increased the incidence of lymphadenopathy of many
causes57.
Other operational studies from Karonga have demonstrated that individuals with less certain
diagnoses of tuberculosis (ie lack of culture confirmation, or positive results from a single
specimen only) are at higher risk of mortality49, independent of HIV status, presumably due
to other (untreated) pathology. A high proportion of chronic cough suspects in this setting
who are not diagnosed with tuberculosis are HIV-positive and exhibit clinical syndromes
consistent with WHO Stage 3 or Stage 4 AIDS58 and should be referred directly to
antiretroviral therapy (ART) services.
Treatment
The KPS follows standard Malawi treatment protocols for tuberculosis, and thus is well-
placed to provide reliable, consistent long-term data on the prevalence of drug-resistance in
a rural African population with a moderate HIV prevalence and a well-functioning
tuberculosis control programme. To date, second-line drugs are not widely available. Initial
drug resistance to one or more drugs has consistently been around 10% and multi-drug
resistance is rare, at less than 1%, with no increase over the past 20 years 59-61.
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In other analyses of routine KPS data, it was established that reported treatment outcome is
misleading if based solely on registered patients, since diagnosed patients who die or default
before registration are excluded. In Karonga case fatality rates were 16% among all
diagnosed smear-positive patients, compared to 13% of those registered for treatment49.
This observation led to a call for National Tuberculosis Programmes to use diagnosed rather
than registered patients as the denominator for treatment outcome statistics62.
Karonga has participated in two multicentre studies to evaluate enhancement of tuberculosis
treatment. A randomised placebo-controlled trial demonstrated that immunotherapy with
single-dose M.vaccae has no place as an adjunct to standard tuberculosis treatment in HIV-
positive adults63. An open trial with a historical comparison cohort showed that even in a
country where co-trimoxazole is standard first line treatment for several diseases in adults
and children, and where sulfadoxine-pyrimethamine was first line treatment for malaria
(thereby making the presence of co-trimoxazole resistant organisms more likely), a
prophylactic 12 month course of co-trimoxazole in HIV-positive tuberculosis patients had a
significant impact on mortality, averting one death during the 18 months post-registration
for every 12.5 HIV-positive tuberculosis patients treated64. The results of this study were a
major factor leading to country-wide adoption of co-trimoxazole into standard care for all
HIV-positive tuberculosis patients in Malawi.
Genetic susceptibility
Genetic susceptibility to tuberculosis and leprosy has been studied using multi-case family
trees that can be drawn up from Karonga databases, and in large multi-centre case-control
studies. These studies have contributed to methodological work on family sampling in
genetics studies65, and found that several genetic associations with tuberculosis seen in other
populations (variants of vitamin D receptor, interferon-γ, mannose-binding lectin, and
Solute Carrier family 11 [SLC11A1, formerly NRAMP1]) could not be replicated in this
population. Other polymorphisms appear to be associated with tuberculosis in Karonga: for
example an untranslated region of SLC11A1 (associated with protection) and Q1022H in
Complement Receptor 1 (associated with susceptibility)66. Some associations found in
Karonga differed by HIV status, suggesting that the role of innate immune responses may be
materially altered in the immunocompromised host66. Further analyses as part of a multi-
centre study have suggested a protective effect of the CD209-336G variant allele of the
DC_SIGN receptor67 and work is ongoing.
BCG
BCG has been studied intensively in Karonga, in terms of efficacy, immune responses, the
interpretation of BCG scars and the effect of BCG on subsequent DTH to tuberculin. Two
large studies of BCG efficacy were conducted, the first a cohort study based on over 80,000
individuals, defined by BCG scar status68 (many of whom had been vaccinated in mass
campaigns carried out in schoolchildren), and the second a randomised controlled trial of
single versus repeat BCG in over 120,000 individuals, with a 5 to 9 year follow-up69. The
cohort study established that although BCG provided 50% protection against leprosy, no
protection against tuberculosis was demonstrable in this population (and scar size did not
correlate with protection against either disease70). The trial confirmed that the lack of
protection against tuberculosis was not overcome by repeating the vaccination in adults,
although the protection against leprosy was improved69. This is one of the results underlying
WHO’s recommendation against giving BCG boosters.
The findings in the Karonga studies were important in that they established that the failure
of BCG in this population was a specific deficit in BCG’s action against tuberculosis: effects
against leprosy were clear cut and supported continuation of the BCG programme in the
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efforts to eliminate leprosy. The findings related to leprosy also allayed concerns over
methodological issues such as attribution of vaccine status by scar observation in the cohort
study. It is known, from a district-wide blinded study in Karonga, that less than 60% of
children vaccinated as infants have a recognisable scar 3 years later, and that scar reading is
subject to considerable observer variation particularly in young children71. Even BCG given
in the controlled circumstances of the efficacy trial failed to produce a scar in approximately
7% of individuals aged between 3 months and 60 years at the time of vaccination8, and more
than 20% of infants vaccinated before one month of age did not have a recognisable scar at 4
years of age8. This has implications not only for efficacy studies, but also for vaccine uptake
surveys8,71.
The need to elucidate the relationship between reactogenicity (ability to induce scars and
ulcers), immunogenicity (ability to induce DTH or cytokines) and protection (afforded
against tuberculosis and leprosy) in the response to BCG vaccination 72 and the different
actions of BCG in different settings, resulted in further studies of BCG in Karonga, and in
parallel studies in the UK (in the UK, adolescent BCG vaccination has been shown to be
protective against pulmonary tuberculosis).
Efficacy of BCG in stimulating immune response and difference between
populations
Placebo controlled studies of immune responses to BCG amongst young adults and
adolesents in Karonga and in the UK used a diluted whole blood assay73 in which cytokines
produced by monocytes could be measured in 24-hour culture supernatants by ELISA74 or
IFN-γ and other T cell derived cytokines could be measured after 6 days incubation9. Using
these assays, Malawian subjects were shown to produce higher amounts of proinflammatory
cytokines such as TNF-α, IL-1β and IL-10 than UK subjects74. T cell responses to
M.tuberculosis PPD and several other mycobacterial antigens were assessed in terms of
IFN-γ production before and one year after BCG vaccination of young adults and
adolescents in Malawi and the UK. A much higher proportion of Malawian than UK
subjects were IFN-γ responders prior to vaccination whereas this proportion was similar
(approximately 80%) between the two populations one year after vaccination75. This
difference probably reflects more extensive prior exposure to environmental mycobacteria76
in Malawi compared to the UK 77, although we were unable to demonstrate an association
between prior in vitro sensitivity to antigens from particular environmental mycobacteria in
the UK and failure to increase IFN-γ production following vaccination78,79. Using an assay
to detect clonal T cell expansions, new T cell clones were detected in the Malawians
following vaccination80, but such immunity may be lost over time following exposure to the
many other infections in a rural African setting. Studies in BCG vaccinated infants in
Malawi and the UK, showed that there are differences in how infants respond to vaccination
in the two settings3, suggesting that response is influenced by factors other than life-time
exposure to environmental mycobacteria. These comparative studies highlight that the
immune system is probably configured and maintained differently in an African compared
to a European setting, with implications for both the induction and maintenance of vaccine-
induced immunity.
Environmental mycobacteria: their role in M.tuberculosis infection, disease
and immune response
Environmental mycobacteria have been an important theme in KPS studies: they induce
non-specific tuberculin reactivity and so must be considered in interpreting tuberculin
surveys and in vitro immunological assays with mycobacterial antigens; they contaminate
Crampin et al. Page 9
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2012 February 05.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
sputum specimens and appear as acid fast bacilli in sputum smears, necessitating culture for
definitive diagnoses of tuberculosis; and exposure to them may influence the effectiveness
of BCG vaccination.
Several studies have shown a widespread and heterogeneous environmental mycobacterial
flora in Karonga. Examination of soil and water samples by culture, acid fast staining and
PCR, or by direct PCR using 16S rRNA revealed evidence for ubiquitous mycobacteria81.
Several isolates were members of the M fortuitum complex, but speciation proved difficult,
and it is likely many of the local mycobacteria have not been characterised. Over 13 years,
474 non-tuberculous mycobacteria were identified in Karonga sputum cultures by our UK
reference laboratory. More than half were in the M avium-intracellulare complex, and 25 %
were M fortuitum, with a wide range of less common species82, all adding to the evidence
for a rich mycobacterial flora in contact with humans.
On a larger scale, more than 36,000 individuals were skin tested during the early 1980s, with
15 antigens from 12 environmental mycobacteria82. Detailed analyses of these results by
age, sex and BCG scar status revealed considerable variation in the frequency of sensitivity
to these antigens. The highest prevalence was noted to antigens of M avium, intracellulare
and scrofulaceum (“MAIS” complex), among the slow grower group, and to one of three M
fortuitum antigens among the fast growers (corresponding to frequencies found in sputa).
Sensitivity to antigens of several of the slow-growers (M avium, M intracellulare, M
kansasii, M marinum, and M scrofulaceum) was increased significantly in individuals with a
BCG scar, reflecting cross reactivity of these organisms, all of which are known to be close
relatives of M.tuberculosis. In analysis of subsequent tuberculosis and leprosy incidence,
prior sensitivity to antigens of fast growers (eg M fortuitum) but not to antigens of slow
growers, was associated with 70 % lower incidence of both tuberculosis (p = 0.08) and
leprosy (p = 0.05). This was unexpected, as we had predicted that sensitivity to slow
growers would be most strongly associated with reduced incidence of tuberculosis and
leprosy as found elsewhere83, given that M.tuberculosis and M leprae are classified with the
slow growers. The agreement between the effects on tuberculosis and leprosy supports the
validity of the KPS results, but the mechanism is unclear. It may reflect particular antigenic
properties of the mycobacteria prevalent in the Karonga environment, and the observation is
also consistent with hypotheses that “specific” DTH responses (ie to closely related
antigens) are associated more with immunopathology than with protection84,85.
Related to these studies, six isolates of three species of non-tuberculous mycobacteria from
Karonga (M avium, M cheloni, M fortuitum) were included in collaborative experiments on
mycobacterial vaccines in mice86. Only the M avium strains replicated in mice, and prior
exposure to M avium alone inhibited replication of BCG bacilli given subsequently. This
suggests blocking of BCG’s action by prior environmental mycobacterial exposure, rather
than masking of BCG’s effect as originally proposed and demonstrated87. It might explain
why BCG given to adults failed to protect against tuberculosis in Karonga, although it does
not explain why BCG protected against leprosy in the same trial (although a relatively weak
immune response may be sufficient to inhibit M leprae). Given that BCG vaccination is now
given only to young infants, too early for prior environmental mycobacterial infection, we
still suspect that the influence of these other mycobacterial infections is more in masking
than in blocking of BCG.
Summary
The Karonga programme has allowed exploration of many aspects of the interaction
between M.tuberculosis and the human host in a single population: from genetic
predisposition to infection and disease, through risks of infection, development of disease,
Crampin et al. Page 10
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2012 February 05.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
disease trends, the influence of HIV and environmental mycobacteria and the complex
action of BCG vaccine. The combination of all these studies in a rigorous, broad, and long-
term framework puts each of the separate findings in context, making them more
interpretable, and generalisable. They highlight the complex nature of the relationship of
M.tuberculosis (and M.leprae) with the immune system of the host. With no other pathogen
is there evidence that incidental exposures to related species have such a profound effect on
risk, on response to vaccines and on interpretation of measures of infection and protection.
The relationship between HIV and tuberculosis is also special, having an evolving
synergistic relationship that exacerbates the severity of each. Tuberculosis has always been
an opportunist and HIV has facilitated its re-mergence as described in Karonga and
throughout the world. In addition to the basic science research carried out by the KPS, the
relationship with the NTP has facilitated operational investigations into drug resistance,
treatment outcome, co-trimoxazole preventive therapy and optimal diagnostic use of
microscopy services.
Future of tuberculosis and tuberculosis research in Karonga district
The KPS continues its epidemiological and immunological research on tuberculosis,
including participation in multicentre studies exploring markers of M.tuberculosis infection,
disease and protection. The advent of ART has already been shown to have a measurable
effect on mortality at population level in the district88 and it is likely that the epidemiology
of tuberculosis will change. The effect is unpredictable - gains made may be
counterbalanced by the increasing survival of a large cohort of chronically
immunosuppressed individuals at moderate to high risk of tuberculosis and the emergence of
tuberculosis associated with immune-reconstitution disease. The KPS involvement with
tuberculosis control, HIV surveillance and ART delivery in Karonga district is ongoing in
both a research and operational capacity. Current and future studies should make an
important contribution to the identification of new challenges, and appropriate responses in
this new era of tuberculosis in sub-Saharan Africa.
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Figure 1.
Map of Karonga
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Figure 2.
Frequency distributions of induration to RT23 in females with no BCG scar by age, Karonga
district 1980-1984
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Figure 3.
Prevalence of induration greater than 10 mm, by age, sex and BCG scar status, Karonga
1980-1984.
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Figure 4.
DTH response to tuberculin and time since vaccination, among individuals aged <15 who
were BCG scar negative at vaccination.
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Figure 5.
Rate of smear-positive pulmonary tuberculosis in adults aged 15-49, Karonga, 1998-2005.
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Figure 6.
Relative risk of TB in HIV-positive vs HIV-negative adults in northern Malawi, by age
group
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Figure 7.
Ratio of male to female cases of smear-positive pulmonary tuberculosis by age group over
time.
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